Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical...

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• Angiogenesis is a key target for cancer therapy, with current treatments focusing on VEGF/VEGFR pathways.
• Approved anti-angiogenic therapies include monoclonal antibodies and multikinase inhibitors.
• Emerging evidence highlights the role of specific enzymes in tumor-driven angiogenesis.

Purpose of the Study:

• To review current knowledge on enzymatic targets in tumor-driven angiogenesis.
• To explore the potential clinical applications of modulating these enzymatic targets.
• To identify promising novel therapeutic strategies for cancer treatment.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of enzymatic pathways involved in angiogenesis.
• Evaluation of the efficacy and suitability of enzyme inhibitors for clinical application.

Main Results:

• Metalloproteinase and nitric oxide synthase inhibitors have shown limited clinical success.
• Early clinical studies of heparanase, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, lysyl oxidase (LOX), and angiotensin-converting enzyme (ACE) inhibitors show promising results.
• These enzymes represent potential targets for novel anticancer therapies.

Conclusions:

• Heparanase, NADPH oxidase, LOX, and ACE are identified as promising enzymatic targets for anticancer therapy.
• Modulation of these enzymes could lead to more effective anti-angiogenic treatments.
• Further clinical investigation is warranted to validate these findings.